Cellular and animal models for high-throughput screening of therapeutic agents for the treatment of the diseases of the elderly in general and alzheimer's disease in particular

Frontiers in Pharmacology

Volumn 4 MAY, Issue , 2013, Pages

  Holtzman, Jordan L ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Amyloid ; Chaperones; Dementia; N glycosylation; Protein processing

Indexed keywords

ABETA VACCINE; AMYLOID BETA PROTEIN; BAPINEUZUMAB; CALNEXIN; CALRETICULIN; CHAPERONE; DOCOSAHEXAENOIC ACID; ERP55 PROTEIN; ERP57 PROTEIN; ERP72 PROTEIN; ESTROGEN; GESTAGEN; GLUCOSE REGULATED PROTEIN 78; HERBACEOUS AGENT; IBUTAMOREN; MEMBRANE PROTEIN; MYELIN; PLACEBO; SEMAGACESTAT; SOLANEZUMAB; TARENFLURBIL; UNCLASSIFIED DRUG; VACCINE; ALZHEIMER DISEASE VACCINE; CYCLIN DEPENDENT KINASE INHIBITOR 1C;

AGED; AGING; ALZHEIMER DISEASE; ARTICLE; BRAIN NERVE CELL; CATALYSIS; CEREBROSPINAL FLUID; COGNITION; COMPLEX FORMATION; DEMENTIA; DISEASE MODEL; DRUG DEVELOPMENT; DRUG RESEARCH; ENDOPLASMIC RETICULUM; GENE MUTATION; GINKGO BILOBA; GLYCOSYLATION; HIGH THROUGHPUT SCREENING; HUMAN; MEMORY; MITOCHONDRION; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN PROCESSING; PROTEIN SYNTHESIS; SYNAPSE; TRANSGENIC MOUSE; AGE; BRAIN CORTEX; CELL MODEL; CLINICAL FEATURE; CORRELATION ANALYSIS; EXTRACELLULAR SPACE; GENETIC TRANSFECTION; MOUSE; NEUROTOXICITY; SYNAPTIC MEMBRANE;

EID: 84881529799     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2013.00059     Document Type: Article

References (54)

1. Abramowski, D., Wiederhold, K. H., Furrer, U., Jaton, A. L., Neuenschwander, A., Runser, M. J., et al. (2008). Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition. J. Pharmacol. Exp. Ther. 327, 411-424.
2. Aiyar, N., Bennett, F., Nambi, P., Valinski, W., Angioli, M., Minnich, M., et al. (1989). Solubilization of rat liver vasopressin receptors as a complex with a guanine-nucleotide-binding protein and phosphoinositide-specific phospholipase C. Biochem. J. 261, 63-70.
3. Bennett, C. F., Balcarek, J. M., Varrichio, A., and Crooke, S. T. (1988). Molecular cloning and complete amino-acid sequence of form-1 phophoinositide-specific phospholipase C. Nature 334, 268-270.
4. Batlevi, Y., and La Spada, A. R. (2011). Mitochondrial autophagy in neural function, neurodegenerative disease, neuron cell death, and aging. Neurobiol. Dis. 43, 46-51.
5. Blennow, K., Zetterberg, H., Rinne, J. O., Salloway, S., Wei, J., Black, R., et al. (2012). Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch. Neurol. 69, 1002-1010.
6. Calon, F., Lim, G. P., Yang, F., Morihara, T., Teter, B., Ubeda, O., et al. (2004). Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 43, 633-645.
7. Carro, E., Trejo, J. L., Gomez-Isla, T., LeRoth, D., and Torres-Aleman, L. (2002). Serum insulin-like growth 1 regulates brain amyloid-β levels. Nat. Med. 12, 1390-1397.
8. Carroll, J. C., Rosario, E. R., Chang, L., Stanczyk, F. Z., Oddo, S., LaFerla, F. M., et al. (2007). Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice. J. Neurosci. 27, 13357-13365.
9. Dawson, G. R., Seabrook, G. R., Zheng, H., Smith, D. W., Graham, S., O'Dowd, G., et al. (1999). Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the beta-amyloid precursor protein. Neuroscience 90, 1-13.
10. DeKosky, S. T., Williamson, J. D., Fitzpatrick, A. L., Kronmal, R. A., Ives, D. G., Saxton, J. A., et al. (2008). Ginkgo biloba for revention of dementia: a randomized controlled trial. JAMA 300, 2253-2262.
11. De Strooper, B., Vassar, R., and Golde, B. (2010). The secretases: enzymes with therapeutic potential in Alzheimer's disease. Nat. Rev. Neurol. 6, 99-107.
12. Doody, R. S. (2012). Safety and efficacy of solanezumab in patients with mild to moderate Alzheimer's Disease: results of phase 3. J. Nutr. Health Aging (abstr.) 16, 801-801.
13. Erickson, R. R., Dunning, L. M., Olson, D. A., Cohen, D. A., Davis, A. T., Wood, W. G., et al. (2005). In cerebrospinal fluid ER chaperones ERp57 and calreticulin bind B-amyloid. Biochem. Biophys. Res. Commun. 332, 50-57.
14. Erickson, R. R., Dunning, L. M., and Holtzman, J. L. (2006). The effect of aging on the chaperone concentrations in the hepatic, endoplasmic reticulum of male rats: the possible role of protein misfolding due to the loss of chaperones in the decline in physiological function seen with age. J. Gerontol. Biol. Med. 61A, 435-443.
15. Espeland, M. A., Rapp, S. R., Shumaker, S. A., Brunner, R., Manson, J. E., Sherwin, B. B., et al. (2004). Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291, 2959-2968.
16. Friedman, J. R., Lackner, L. L., West, M., DiBenedetto, J. R., Nunnari, J., and Voeltz, G. K. (2011). ER tubules mark sites for mitochondrial division. Science 334, 358-362.
17. Green, R. C., Schneider, L. S., Amato, D. A., Beelen, A. P., Wilcock, G., Swabb, E. A., et al. (2009). Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 302, 2557-2564.
18. Hayashi, T., Rizzuto, R., Hajnoczky, G., and Su, T.-P. (2009). MAM: more than just a housekeeper. Trends Cell Biol. 18, 81-88.
19. Helenius, J., and Aebi, M. (2002). Transmembrane movement of dolichol linked carbohydrates during N-glycoprotein biosynthesis in the endoplasmic reticulum. Semin. Cell Dev. Biol. 13, 171-178.
20. Herzog, V., Kirfel, G., Siemes, C., and Schmitz, A. (2004). Biological roles of APP in the epidermis. Eur. J. Cell Biol. 83, 613-624.
21. Holmes, C., Bache, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., et al. (2008). Long-term effects of Aβ 42 immunisation in Alzheimer's disease: follow-up of a randomized, placebo-controlled phase 1 trial. Lancet 372, 216-223.
22. Hu, X., Zhou, X., He, W., Yang, J., Xiong, W., Wong, P., et al. (2010). BACE1 deficiency causes altered neuronal activity and neurodegeneration. J. Neurosci. 30, 8819-8829.
23. Imbimbo, B. P., Ottonello, S., Frisardi, V., Solfrizzi, V., Greco, A., Seripa, D., et al. (2012). Solanezumab for the treatment of mild-to-moderate Alzheimer's Disease. Expert Rev. Clin. Immunol. 8, 135.
24. Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., et al. (2000). Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979-982.
25. Kelleher, D. J., and Gilmore, R. (2006). An evolving view of the eukaryotic oligosaccharyltransferase. Glycobiology 16, 47R-62R.
26. Kousvelari, E. E., Banerjee, D. K., Murty, L., and Baum, B. J. (1988). N-linked protein glycosylation in the rat parotid gland during aging. Mech. Ageing Dev. 42, 173-181.
27. Kukar, T., Prescott, S., Eriksen, J., Holloway, V., Murphy, M. P., Koo, E. H., et al. (2007). Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci. 8:54. doi: 10.1186/1471-2202-8-54
28. Laird, F., Gai, H., Savone, A. V., Farah, M. H., He, K., Melinikova, T., et al. (2005). BACE1, a major determinant of selective vulnerability of the brain to amyloid-β amyloidogenesis, essential for cognitive, emotional and synaptic functions. J. Neurosci. 25, 11693-11709.
29. Levin-Allerhand, J. A., Lominska, C. E., Wang, J., and Smith, J. D. (2002). 17Alpha-estradiol and 17beta-estradiol treatments are effective in lowering cerebral amyloid-beta levels in AbetaPPSWE transgenic mice. J. Alzheimer's Dis. 4, 449-457.
30. Marino, M., Dolfi, C., Paradiso, C., Cavallini, G., Masini, M., Gori, Z., et al. (1998). Age-dependent accumulation of dolichol in rat liver: is tissue dolichol a biomarker of aging? J. Gerontol. A Biol. Sci. Med. Sci. 53, B87-B93.
31. Merkwirth, C., and Langer, T. (2008). Mitofusin 2 builds a bridge between ER and mitochondria. Cell 135, 1165-1167.
32. Militello, D., and Colombo, M. I. (2011). A membrane is born: origin of the autophagosomal compartment. Curr. Mol. Med. 11, 197-203.
33. Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C., Hardy, J., et al. (2000). A(β peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982-985.
34. Morrell, S. L., Fuchs, J. A., and Holtzman, J. L. (2000). The effect of methoxychlor administration to male rats on the hepatic, microsomal iodothyronine 5′-deiodinase, form I. J. Pharmacol. Exp. Ther. 294, 308-312.
35. Mota, O. M., Huang, G. T., and Kukuruzinska, M. A. (1994). Developmental regulation and tissue-specific expression of hamster dolichol-P-dependent N-acetylglucosamine-1-P transferase (GPT). Biochem. Biophys. Res. Commun. 204, 284-291.
36. Nemere, I. (2005). The 1,25D3-MARRS protein: contribution to steroid stimulated calcium uptake in chicks and rats. Steroids 70, 455-457.
37. Nemere, I., Farach-Carson, M. C., Rohe, B., Sterling, T. M., Norman, A. W., Boyan, B. D., et al. (2004). Ribozyme knockdown functionally links a 1,25(OH)2D3 membrane binding protein (1,25D3-MARRS) and phosphate uptake in intestinal cells. Proc. Natl. Acad. Sci. U.S.A. 101, 7392-7397.
38. Nikolaev, A., McLauglin, T., O'Oleary, D. D. M., and Tessier-Lavigne, M. (2009). APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 457, 981-989.
39. Pan, T., Kondo, S., Le, W., and Jankovic, J. (2008). The role of autophagy-lysomome pathway in neurodegeneration associated with Parkinson's disease. Brain 131, 199-1978.
40. Pottier, C., Wallon, D., Lecrux, A. R., Maltete, D., Bombois, S., Jurici, S., et al. (2012). Amyloid-β protein precursor gene expression in Alzheimer's Disease and other conditions. J. Alzheimers Dis. 28, 561-566.
41. Quinn, J. F., Raman, R., Thomas, R. G., Yurko-Mauro, K., Nelson, E. B., Van Dyck, C., et al. (2010). Docosahexaenoic acid supplementation and cognitive decline in Alzheimer's disease. JAMA 341, 1903-1911.
42. Rajapaksha, T., Eimer, W. A., Bozza, T. C., and Vassar, R. (2011). The Alzheimer's β -secretase enzyme BACE1 is required for accurate axon guidance of olfactory sensory neurons and normal glomerulus formation in the olfactory bulb. Mol. Neurodegener. 6, 88.
43. Scheltens, P., Sperling, R., Salloway, S., and Fox, N. (2012). Bapineuzumab IV phase 3 results. J. Nutr. Health Aging (abstr.) 16, 797.
44. Schon, E. A., and Przedborski, S. (2011). Mitochondria: the next (neurode) generation. Neuron 70, 1033-1053.
45. Schor, N. F. (2011). What the halted phase III γ -secretase inhibitor trial may (or may not) be telling us. Ann. Neurol. 69, 237-239.
46. Sevigny, J. J., Ryan, J. M., van Dyek, C. H., Peng, Y., Lines, C. R., and Nessly, M. I. (2008). Growth hormone secretagogue MK-677; No clinical effect on AD progression in a randomized trial. Neurology 71, 1702-1708.
47. Srivastava, S. P., Chen, N.-Q., Liu, Y.-X., and Holtzman, J. L. (1991). Purification and characterization of a new isozyme of thiol:protein disulfide oxidoreductase from rat hepatic microsomes: relationship of this isozyme to cytosolic, phosphatidylinositol specific phospholipase C form 1A. J. Biol. Chem. 266, 20337-20344.
48. Srivastava, S. P., Fuchs, J. A., and Holtzman, J. L. (1993). The reported cDNA sequence for phospholipase Ca encodes protein disulfide isomerase, isozyme Q-2 and not phospholipase C. Biochem. Biophys. Res. Commun. 193, 971-979.
49. Stackman, R. W., Eckenstein, F., Frei, B., Kulhanek, D., Nowlin, J., and Quinn, J. F. (2003). Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment. Exp. Neurol. 184, 510-520.
50. Vellas, B., Coley, N., Ousset, P.-J., Berrut, G., Dartigues, J.-F., Dubois, B., et al. (2012). Long-term use of standardize Ginkgo biloba extract for the prevention of Alzhimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol. 11, 851-859.
51. Veterans Administration Cooperative Study Group on Antihypertensive Agents. (1967). Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 202, 116-122.
52. Veterans Administration Cooperative Study Group on Antihypertensive Agents. (1970). Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 213, 1143-1152.
53. Wischik, C. M. (2012). Limitations of MTC (methylene blue) and replacement LMTXTM in TauRx phase 3 program. J. Nutr. Health Aging (abstr.) 16, 842.
54. Yan, Q., and Lennarz, W. J. (1999). Oligosaccharyltransferase: a complex multisubunit enzyme of the endoplasmic reticulum. Biochem. Biophys. Res. Commun. 266, 684-689.